201 related articles for article (PubMed ID: 23816608)
1. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.
Lun X; Ruan Y; Jayanthan A; Liu DJ; Singh A; Trippett T; Bell J; Forsyth P; Johnston RN; Narendran A
Mol Oncol; 2013 Oct; 7(5):944-54. PubMed ID: 23816608
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
[TBL] [Abstract][Full Text] [Related]
6. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
Chalikonda S; Kivlen MH; O'Malley ME; Eric Dong XD; McCart JA; Gorry MC; Yin XY; Brown CK; Zeh HJ; Guo ZS; Bartlett DL
Cancer Gene Ther; 2008 Feb; 15(2):115-25. PubMed ID: 18084242
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor.
Akinlolu O; Ottolino-Perry K; McCart JA; Reilly RM
Cancer Biother Radiopharm; 2010 Jun; 25(3):325-33. PubMed ID: 20578838
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.
Jiang B; Lun X; Hao X; Wang Y; Yin X; Huang D; He W; Wang Z
Biomed Pharmacother; 2017 Nov; 95():1201-1208. PubMed ID: 28931212
[TBL] [Abstract][Full Text] [Related]
10. Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells.
Thakur S; Ruan Y; Zhang C; Lun X; Jayanthan A; Narendran A
Cancer Gene Ther; 2021 Aug; 28(7-8):739-744. PubMed ID: 32678303
[TBL] [Abstract][Full Text] [Related]
11. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
12. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
13. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
15. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
16. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
17. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
[TBL] [Abstract][Full Text] [Related]
18. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
19. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.
Weibel S; Hofmann E; Basse-Luesebrink TC; Donat U; Seubert C; Adelfinger M; Gnamlin P; Kober C; Frentzen A; Gentschev I; Jakob PM; Szalay AA
J Transl Med; 2013 May; 11():106. PubMed ID: 23635329
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.
Ehrig K; Kilinc MO; Chen NG; Stritzker J; Buckel L; Zhang Q; Szalay AA
J Transl Med; 2013 Mar; 11():79. PubMed ID: 23531320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
